Generic clozapine: Outcomes after switching formulations

British Journal of Psychiatry

Volumn 189, Issue AUG., 2006, Pages 184-185

  Paton, Carol ^a  

^a OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GENERIC DRUG;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SUBSTITUTION; HUMAN; LICENCE; MAJOR CLINICAL STUDY; MENTAL HEALTH SERVICE; SCHIZOPHRENIA; SCORING SYSTEM; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; UNITED KINGDOM;

ANTIPSYCHOTIC AGENTS; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; CLOZAPINE; DRUG ADMINISTRATION SCHEDULE; DRUGS, GENERIC; HUMANS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33747152859     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.bp.105.017079     Document Type: Article

References (11)

1. Anon (2001) Comparison of the bioequivalence of generic versus branded clozapine. Journal of Clinical Psychiatry, 62 (suppl. 5), 23-24.
2. Eresneftky, L. & Glazer, W. M. (2001) Comparison of the bioequivalence of generic versus branded clozapine. Journal of Clinical Psychiatry, 62 (suppl. 5), 25-28.
3. Guy, W. (ed.) (1976) ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338, pp. 217-222. Rockville, MD: US Department of Health, Education and Welfare.
4. Kluznik, J. C., Walbek, N. H., Farnsworth, M. G., et al (2001) Clinical effects of a randomised switch of patients from Clozaril to a generic clozapine. Journal of Clinical Psychiatry, 62 (suppl. 5), 14-17.
5. Lam, Y. W., Ereshefaky, L., Toney, G. B., et al (2001) Branded versus generic clozapine: bioavailability comparison and interchangeability issues. Journal of Clinical Psychiatry, 62 (suppl. 5), 18-22.
6. Makela, E. H., Cutlip, W. D., Stevenson, J. M., et al (2003) Branded versus generic clozapine for treatment of schizophrenia. Annals of Pharmacotherapy, 37, 350-353.
7. Mofeen, R. & Baiter, J. (2001) Case reports of the reemergence of psychotic symptoms after conversion from brand name clozapine to a generic formulation. Clinical Therapeutics, 23, 1720-1731.
8. National Institute for Clinical Excellence (2003) Atypical Antipsychotics in the Treatment of Schizophrenia. Health Technology Appraisal No 43. London: National Institute for Clinical Excellence.
9. Sajbel, T. A., Carter, G. W. & Wiley, R. B. (2001) Converting patients from brand-name clozapine to generic clozapine. Annals of Pharmacotherapy, 35, 281-284.
10. Stoner, S. C., Lea, J. W., Dubisar, B., et al (2003) A program to convert patients from trade-name to generic clozapine. Pharmacotherapy, 23, 806-810.
11. Wahlbeck, K., Chaine, M. & Essall, M. A. (1999) Clozapine versus typical neuroleptic medication for schizophrenia. The Cochrane Database of Systematic Reviews. Issue 4 (accessed August 2005). Oxford: Update Software.